UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of report (Date of earliest event reported): June 3, 2005

                              --------------------

                              PharmaFrontiers Corp.
                              ---------------------
             (Exact Name of Registrant as Specified in Its Charter)


                                      Texas
                                      -----
                 (State or Other Jurisdiction of Incorporation)

                000-25513                                76-0333165
                ---------                                ----------
        (Commission File Number)            (I.R.S. Employer Identification No.)

    2408 Timberloch Place, Suite B-7
          The Woodlands, Texas                              77380
          --------------------                              -----
(Address of Principal Executive Offices)                  (Zip Code)

       Registrant's telephone number, including area code: (281) 272-9331

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))





Item 8.01   Other Events.

     On June 3, 2005,  Registrant  announced  interim  results of two Phase I/II
clinical trials for Multiple  Sclerosis in a press release.  A copy of the press
release is attached as Exhibit 99.1.


Item 9.01   Financial Statements and Exhibits

    (c) Exhibit 99.1

The following exhibits are to be filed as part of this 8-K:


Exhibit No.          Description
- -----------          -----------
99.1                 Press release issued June 3, 2005


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.




                                       PHARMAFRONTIERS CORP.


                                       By:  /s/ David McWilliams
                                          ----------------------
                                       David McWilliams, Chief Executive Officer

DATE:  June 3, 2005





                                  EXHIBIT INDEX



Exhibit No.          Description
- -----------          -----------
99.1                 Press release issued June 3, 2005.